跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
JN-2
首页
药物
JN-2
JN-2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANTS JN.1, BA.2.86, AND XBB LINEAGES, DRUG FOR COMBINED USE, AND USE
申请人: WESTVAC BIOPHARMA CO LTD
优先权: 2024
CN
WO
3 件公开
RECOMBINANT PROTEIN VACCINE FOR PREVENTING AND TREATING SARS-COV-2 VARIANT JN.1, BA.2.86, AND XBB LINEAGES, COMBINATION DRUG AND USE
申请人: WESTVAC BIOPHARMA CO LTD
优先权: 2024
WO
Anti-Omicro BA.2. 86 type novel coronavirus antibody or antigen-binding fragment thereof and application of anti-Omicro BA.2. 86 type novel coronavirus antibody or antigen-binding fragment thereof
申请人: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL CO LTD
优先权: 2025
CN
Ankara vaccinia virus genetic engineering vaccine for pig replication and respiration complex
申请人: WUCHANG SHIPBUILDING IND CO
优先权: 2006
CN
Lycium barbarum fermented product with liver protection function as well as preparation method and application of lycium barbarum fermented product
申请人: UNIV JIANGNAN
优先权: 2026
CN
Novel coronavirus broad-spectrum neutralizing antibody and application thereof
申请人: INST MILITARY MEDICINE ACADEMY MILITARY SCIENCES PLA
优先权: 2026
CN
T cell immunodominance epitope peptide of SARS-CoV-2 nucleocapsid protein mutation site and application of T cell immunodominance epitope peptide
申请人: THE 8TH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV SHENZHEN FUTIAN
优先权: 2025
CN
2 件公开
Preparation method of dronedarone hydrochloride key intermediate JN-02
申请人: JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD
优先权: 2025
CN
药物
反馈